Upstream Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.2M+33.2% YoYTTM through 30 Jun 2026
Net Income -$156.5MTTM through 30 Jun 2026
Free Cash Flow -$136.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -561,882.0% |
| Net Margin | -4,955.7% |
Returns
-42.2%ROE
-40.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio23.14x
Net Debt-$293.5Mnet cash position
Cash & Equivalents$79.4M
Quality Metrics
Altman Z-Score14.77
Piotroski F-Score3 / 9
FCF Margin-4,321.2%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $2.9M
Diluted EPS-$2.88TTMFY2025: $-2.66
Dividend
No dividend
Capital Allocation
Capex Intensity3.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and Licensing | $2.9M | +20.3% | View detailsPre-commercial clinical-stage operations; revenue is derived from licensing agreements and is not yet driven by commercial product sales. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.